KRE vs XBI
SPDR S&P Regional Banking ETF vs SPDR S&P Biotech ETF
- • KRE pays a higher dividend yield (2.14%).
Side-by-side metrics
| Metric | KRE | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.14% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $4.74B | $10.73B |
YTD return | 14.47% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.18 | 1.10 |
P/E ratio | 13.46 | — |
Last price | $74.92 | $164.01 |
Inception | — | — |
Issuer | State Street | State Street |
KRE top holdings
| PNFP | Pinnacle Financial Partners Inc | 1.37% |
| UMBF | UMB Financial Corp | 1.37% |
| AUB | Atlantic Union Bankshares Corp | 1.37% |
| CFG | Citizens Financial Group Inc | 1.36% |
| GBCI | Glacier Bancorp Inc | 1.36% |
| ASB | Associated Banc-Corp | 1.36% |
| CFR | Cullen/Frost Bankers Inc | 1.35% |
| FULT | Fulton Financial Corp | 1.35% |
| FIBK | First Interstate BancSystem Inc | 1.35% |
| WBS | Webster Financial Corp | 1.35% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About KRE
KRE (SPDR S&P Regional Banking ETF) is US regional bank stocks. Managed by State Street, the fund carries $4.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 2.14%. Its largest holding is Pinnacle Financial Partners Inc (PNFP), which represents 1.4% of the portfolio. Financial Services is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.